Nathan Herrmann, MD, FRCPC
Meta-Analysis
Cannabinoids for Agitation and Aggression in AD
January 29, 2019
Given the limited efficacy and questionable safety profiles of current pharmacologic treatments of agitation in Alzheimer's disease (AD), the therapeutic potential of natural and synthetic cannabinoids are being explored...
Original Research
Lithium Use and Chronic Kidney Disease in Older Adults
August 1, 2017
Could mood-stabilizing medications be increasing patients' risk of developing kidney disease? This large, nested case-control study looks at the degree of risk associated with lithium and valproate treatment in...